Jonathan M Moore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1740884/publications.pdf

Version: 2024-02-01

331670 454955 1,950 35 21 30 citations h-index g-index papers 35 35 35 1715 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Theory and Applications of NMR-Based Screening in Pharmaceutical Research. Chemical Reviews, 2004, 104, 3641-3676.	47.7	313
2	The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chemistry and Biology, 1999, 6, 755-769.	6.0	271
3	Crystal Structure of the Ectodomain Complex of the CGRP Receptor, a Class-B GPCR, Reveals the Site of Drug Antagonism. Structure, 2010, 18, 1083-1093.	3.3	165
4	Solution structure of the major binding protein for the immunosuppressant FK506. Nature, 1991, 351, 248-250.	27.8	157
5	High-resolution solution structure of reduced French bean plastocyanin and comparison with the crystal structure of poplar plastocyanin. Journal of Molecular Biology, 1991, 221, 533-555.	4.2	114
6	NMR screening in drug discovery. Current Opinion in Biotechnology, 1999, 10, 54-58.	6.6	91
7	15N NMR Relaxation Studies of the FK506 Binding Protein: Dynamic Effects of Ligand Binding and Implications for Calcineurin Recognition. Biochemistry, 1994, 33, 4093-4100.	2.5	86
8	NMR experiments for lead generation in drug discovery. Progress in Nuclear Magnetic Resonance Spectroscopy, 2004, 44, 225-256.	7.5	80
9	Nitrogen-15 NMR relaxation studies of the FK506 binding protein: Backbone dynamics of the uncomplexed receptor. Biochemistry, 1993, 32, 9000-9010.	2.5	69
10	Microdrop screening: a rapid method to optimize solvent conditions for NMR spectroscopy of proteins., 1998, 12, 493-499.		59
11	Nuclear Magnetic Resonance-Based Approaches for Lead Generation in Drug Discovery. Methods in Enzymology, 2002, 338, 202-230.	1.0	57
12	Application of NMR SHAPES Screening to an RNA Target. Journal of the American Chemical Society, 2003, 125, 15724-15725.	13.7	51
13	NMR techniques for characterization of ligand binding: Utility for lead generation and optimization in drug discovery., 1999, 51, 221-243.		47
14	Refolding and Characterization of a Soluble Ectodomain Complex of the Calcitonin Gene-Related Peptide Receptor. Biochemistry, 2010, 49, 1862-1872.	2. 5	42
15	Applications of SHAPES Screening in Drug Discovery. Combinatorial Chemistry and High Throughput Screening, 2002, 5, 583-590.	1.1	42
16	Solution structure of FK506 bound to FKBP-12. FEBS Letters, 1992, 302, 89-96.	2.8	37
17	Kinetic studies on 1:1 electron-transfer reactions involving blue copper proteins. 16. Reactivity of plastocyanin from the green alga Scenedesmus obliquus with inorganic redox partners and related NMR studies. Inorganic Chemistry, 1988, 27, 2306-2312.	4.0	30
18	From Nanodiscs to Isotropic Bicelles: A Procedure for Solution Nuclear Magnetic Resonance Studies of Detergent-Sensitive Integral Membrane Proteins. Structure, 2016, 24, 1830-1841.	3.3	29

#	Article	IF	Citations
19	Combinatorial triple-selective labeling as a tool to assist membrane protein backbone resonance assignment. Journal of Biomolecular NMR, 2012, 52, 197-210.	2.8	27
20	Proton NMR studies of plastocyanin from Scenedesmus obliquus: complete sequence-specific assignment, secondary structure analysis, and global fold. Biochemistry, 1988, 27, 7806-7816.	2.5	25
21	Leveraging structural approaches: applications of NMR-based screening and X-ray crystallography for inhibitor design. Journal of Synchrotron Radiation, 2004, 11, 97-100.	2.4	23
22	Coordination scheme and stereochemical configuration of manganese(II)-adenosine 5'-diphosphate at the active site of 3-phosphoglycerate kinase. Biochemistry, 1985, 24, 5328-5333.	2.5	21
23	Nucleotide-binding Domains of Cystic Fibrosis Transmembrane Conductance Regulator, an ABC Transporter, Catalyze Adenylate Kinase Activity but Not ATP Hydrolysis. Journal of Biological Chemistry, 2006, 281, 4058-4068.	3.4	21
24	Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 845-849.	2.2	18
25	Dynamics of a receptor-bound ligand by heteronuclear NMR: FK506 bound to FKBP-12. Journal of the American Chemical Society, 1993, 115, 4929-4930.	13.7	17
26	Solution Structure of FK506 Bound to the R42K, H87V Double Mutant of FKBP-12. Biochemistry, 1994, 33, 13571-13580.	2.5	13
27	Time-shared experiments for efficient assignment of triple-selectively labeled proteins. Journal of Magnetic Resonance, 2014, 248, 81-95.	2.1	13
28	31P NMR studies of enzyme-bound substrate complexes of yeast 3-phosphoglycerate kinase: III. Two ADP binding sites and their Mg(II) affinity; effects of vanadate and arsenate on enzymic complexes with ADP and 3-P-glycerate. Journal of Inorganic Biochemistry, 1990, 40, 47-57.	3.5	10
29	Dynamic NMR studies of ligandâ€receptor interactions: Design and analysis of a rapidly exchanging complex of FKBPâ€12/FK506 with a 24 kDa calcineurin fragment. Protein Science, 1996, 5, 1917-1921.	7.6	10
30	A redox equilibrator for the preparation of cytochrome oxidase of mixed valence states and intermediate compounds for X-ray synchrotron studies. Analytical Biochemistry, 1982, 124, 239-247.	2.4	4
31	Practical applications of time-averaged restrained molecular dynamics to ligand-receptor systems: FK506 bound to the Q50R,A95H,K98I triple mutant of FKBP-13. Journal of Biomolecular NMR, 1996, 8, 67-76.	2.8	3
32	NMR in fragment-based drug discovery. , 2010, , 41-58.		2
33	Theory and Applications of NMR-Based Screening in Pharmaceutical Research. ChemInform, 2004, 35, no.	0.0	1
34	NMR SHAPES Screening. , 2008, , 1409-1417.		1
35	Fragment-Based NMR Screening in Lead Discovery. , 2007, , 72-98.		1